Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novo Nordisk stops once-weekly semaglutide kidney outcomes trial early following interim analysis

By Brian Buntz | October 12, 2023

Novo Nordisk in the Drug Discovery & Development Pharma 50Novo Nordisk will halt the phase 3b FLOW trial, which investigated the effects of once-weekly injectable semaglutide on kidney outcomes in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).

The company reached the decision following the recommendation of the independent Data Monitoring Committee (DMC), following an interim analysis that met pre-specified criteria for stopping the trial early for efficacy. The company noted that it would maintain the integrity of the trial data, blinding to the results until the trial’s completion. It plans on announcing results in the first half of 2024.

Semaglutide Sales: 2022 vs H1 2023

The FLOW trial was a randomized, double-blind, parallel-group, multinational study that enrolled 3,534 participants across more than 400 investigator sites in 28 countries. The key objective of the trial was to determine the time to first kidney failure, persistent reduction in estimated glomerular filtration rate (eGFR), or death from kidney or cardiovascular causes.

The study, which began in 2019, assessed injectable semaglutide 1.0 mg versus a placebo as an additional treatment to the standard of care. The aim of the trial was to determine if semaglutide can delay the progression of CKD and reduce the risk of death from kidney failure and cardiovascular complications. The trial’s primary composite endpoint included five distinct components, including a decrease in eGFR levels, the need for dialysis or a kidney transplant, and death from kidney or cardiovascular disease in patients with type 2 diabetes and CKD.

In addition to GLP drugs like semaglutide, another class of diabetes medications, including AstraZeneca’s Farxiga and Eli Lilly and Boehringer Ingelheim’s Jardiance, are emerging as potential CKD therapies.

Semaglutide, marketed under the brand name Ozempic, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes and for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

FDA approved semaglutide-based weekly injectable Wegovy to treat adults with obesity in 2021. It extended approval to adolescents 12 years and older in 2022.

Novo Nordisk aims to more than triple sales of its obesity drugs by 2025, which includes Wegovy among others. In 2022, the company projected that obesity drugs sales will exceed more than 25 billion Danish kroner, or about $3.7 billion by 2025.​


Filed Under: clinical trials, Drug Discovery, Nephrology/urology, Regulatory affairs
Tagged With: Biopharma trends, drug discovery, interim analysis, kidney trial, Novo Nordisk, pharmaceutical research, semaglutide
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Illustration of the thought processes in the brain
From gene therapy to vaccines to mitochondrial rescue, the quest for more effective neurodegenerative therapies faces mixed outcomes in 2024
hemodialysis in people on the equipment
Beyond diabetes and obesity: Can GLP-1 therapies also transform chronic disease treatment?
GSK
FDA greenlights Jesduvroq, which GSK hails as ‘first innovative medicine’ for anemia in three decades
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly gets FDA review for empagliflozin in chronic kidney disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE